VAXCYTE, INC. Financing Cash Flow
VAXCYTE, INC. (PCVX) reported Financing Cash Flow of $607.28 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- VAXCYTE, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $5.70M, a 126.41% increase year-over-year.
- VAXCYTE, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $601.58M, a 79159.95% increase year-over-year.
- VAXCYTE, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $2.41M, a 50.93% decline year-over-year.
- VAXCYTE, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$3.67M, a 100.24% decline year-over-year.
- VAXCYTE, INC. net cash provided by (used in) financing activities for fiscal 2025 was $2.01M, a 99.92% decline from fiscal 2024.
- VAXCYTE, INC. net cash provided by (used in) financing activities for fiscal 2024 was $2.45B, a 282.69% increase from fiscal 2023.
- VAXCYTE, INC. net cash provided by (used in) financing activities for fiscal 2023 was $639.81M, a 25.74% decline from fiscal 2022.
- VAXCYTE, INC. net cash provided by (used in) financing activities for fiscal 2022 was $861.55M, a 4741.24% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $607.28M 10-Q · filed 2026-08-05 | $609.69M derived: sum of 3 quarters · filed 2026-08-05 | $606.02M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $601.58M 10-Q · filed 2026-05-06 | $603.99M derived: sum of 2 quarters · filed 2026-05-06 | $600.32M derived: sum of 3 quarters · filed 2026-05-06 | $602.84M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$1.26M derived: sum of 2 quarters · filed 2026-02-24 | $1.25M derived: sum of 3 quarters · filed 2026-08-05 | $2.01M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$3.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$1.15M derived: sum of 2 quarters · filed 2026-08-05 | -$394.00K 10-Q · filed 2025-11-04 | $4.51M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.28M 10-Q · filed 2026-08-05 | $8.18M derived: sum of 3 quarters · filed 2026-08-05 | $1.52B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $759.00K 10-Q · filed 2026-05-06 | $5.67M derived: sum of 2 quarters · filed 2026-05-06 | $1.52B derived: sum of 3 quarters · filed 2026-05-06 | $1.63B derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $4.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.52B derived: sum of 2 quarters · filed 2026-02-24 | $1.63B derived: sum of 3 quarters · filed 2026-02-24 | $2.45B 10-K · filed 2026-02-24 |
| 2024-09-30 | $1.52B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.63B derived: sum of 2 quarters · filed 2025-11-04 | $2.44B 10-Q · filed 2025-11-04 | $2.45B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $110.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $928.56M 10-Q · filed 2025-08-06 | $931.30M derived: sum of 3 quarters · filed 2026-02-24 | $979.85M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $818.20M 10-Q · filed 2025-05-07 | $820.93M derived: sum of 2 quarters · filed 2026-02-24 | $869.48M derived: sum of 3 quarters · filed 2026-02-24 | $1.42B derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $51.28M derived: sum of 2 quarters · filed 2026-02-24 | $598.25M derived: sum of 3 quarters · filed 2026-02-24 | $639.81M 10-K · filed 2026-02-24 |
| 2023-09-30 | $48.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $595.52M derived: sum of 2 quarters · filed 2024-11-05 | $637.08M 10-Q · filed 2024-11-05 | $1.29B derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $546.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $588.53M 10-Q · filed 2024-08-06 | $1.25B derived: sum of 3 quarters · filed 2025-02-25 | $1.29B derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $41.56M 10-Q · filed 2024-05-08 | $698.20M derived: sum of 2 quarters · filed 2025-02-25 | $742.21M derived: sum of 3 quarters · filed 2025-02-25 | $792.09M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $656.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $700.65M derived: sum of 2 quarters · filed 2025-02-25 | $750.53M derived: sum of 3 quarters · filed 2025-02-25 | $861.55M 10-K · filed 2025-02-25 |
| 2022-09-30 | $44.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $93.89M derived: sum of 2 quarters · filed 2023-11-06 | $204.91M 10-Q · filed 2023-11-06 | $213.67M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $49.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $160.90M 10-Q · filed 2023-08-08 | $169.65M derived: sum of 3 quarters · filed 2024-02-27 | $177.25M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $111.02M 10-Q · filed 2023-05-08 | $119.77M derived: sum of 2 quarters · filed 2024-02-27 | $127.37M derived: sum of 3 quarters · filed 2024-02-27 | $128.33M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $8.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $16.35M derived: sum of 2 quarters · filed 2024-02-27 | $17.31M derived: sum of 3 quarters · filed 2024-02-27 | $17.80M 10-K · filed 2024-02-27 |
| 2021-09-30 | $7.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $8.55M derived: sum of 2 quarters · filed 2022-11-07 | $9.04M 10-Q · filed 2022-11-07 | $9.60M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $956.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $1.44M 10-Q · filed 2022-08-08 | $2.00M derived: sum of 3 quarters · filed 2023-02-27 | $2.03M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $487.00K 10-Q · filed 2022-05-09 | $1.04M derived: sum of 2 quarters · filed 2023-02-27 | $1.08M derived: sum of 3 quarters · filed 2023-02-27 | $265.56M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $555.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $591.00K derived: sum of 2 quarters · filed 2023-02-27 | $265.07M derived: sum of 3 quarters · filed 2023-02-27 | $374.87M 10-K · filed 2023-02-27 |
| 2020-09-30 | $36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $264.52M derived: sum of 2 quarters · filed 2021-11-10 | $374.31M 10-Q · filed 2021-11-10 | $415.67M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $264.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $374.28M 10-Q · filed 2021-08-11 | $415.63M derived: sum of 3 quarters · filed 2022-02-28 | $416.00M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $109.80M 10-Q · filed 2021-05-11 | $151.15M derived: sum of 2 quarters · filed 2022-02-28 | $151.52M derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | $41.35M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $41.72M derived: sum of 2 quarters · filed 2022-02-28 | $41.57M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $368.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $215.00K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | -$153.00K 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $62.19M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |